# A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

> **NCT02615691** · PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 120 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** PEGylated Recombinant Factor VIII
- **BIOLOGICAL:** ITI

## Key facts

- **NCT ID:** NCT02615691
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-12
- **Primary completion:** 2024-10-29
- **Final completion:** 2024-10-29
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02615691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02615691, "A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02615691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*